Gastrointestinal Cancer News

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.

Editor’s note: This is the second in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

Next-generation Cologuard exhibited improved colorectal cancer specificity and sensitivity compared with results of the FDA registrational trial that led to approval of the noninvasive screening test, its manufacturer reported.

FDA announced the creation of a voluntary pilot program that will assist clinicians in selecting the appropriate treatment for patients with cancer through the use of laboratory-developed tests, according to an FDA press release.

The addition of pembrolizumab to perioperative chemotherapy failed to significantly extend EFS among patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.

Prognostic models for risk for postoperative cancer recurrence that omit race and ethnicity as predictors may be less accurate for individuals from historically underserved populations, retrospective study results showed.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.

CHICAGO — Fecal microbiota transplantation that contains effective microbiota may overcome resistance to anti-PD-1 therapy among patients with advanced solid cancers, according to data presented at ASCO Annual Meeting.